Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
Aberg JA, Shepherd B, Wang M, Madruga JV, Mendo Urbina F, Katlama C, Schrader S, Eron JJ, Kumar PN, Sprinz E, Gartland M, Chabria S, Clark A, Pierce A, Lataillade M, Tenorio AR. Aberg JA, et al. Among authors: lataillade m. Infect Dis Ther. 2023 Sep;12(9):2321-2335. doi: 10.1007/s40121-023-00870-6. Epub 2023 Sep 26. Infect Dis Ther. 2023. PMID: 37751019 Free PMC article.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Lalezari JP, Latiff GH, Brinson C, Echevarría J, Treviño-Pérez S, Bogner JR, Thompson M, Fourie J, Sussmann Pena OA, Mendo Urbina FC, Martins M, Diaconescu IG, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team. Lalezari JP, et al. Among authors: lataillade m. Lancet HIV. 2015 Oct;2(10):e427-37. doi: 10.1016/S2352-3018(15)00177-0. Epub 2015 Sep 1. Lancet HIV. 2015. PMID: 26423650 Clinical Trial.
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
Morales-Ramirez J, Bogner JR, Molina JM, Lombaard J, Dicker IB, Stock DA, DeGrosky M, Gartland M, Pene Dumitrescu T, Min S, Llamoso C, Joshi SR, Lataillade M. Morales-Ramirez J, et al. Among authors: lataillade m. PLoS One. 2018 Oct 23;13(10):e0205368. doi: 10.1371/journal.pone.0205368. eCollection 2018. PLoS One. 2018. PMID: 30352054 Free PMC article. Clinical Trial.
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHTE Trial Team. Kozal M, et al. Among authors: lataillade m. N Engl J Med. 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493. N Engl J Med. 2020. PMID: 32212519 Clinical Trial.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lataillade M, Lalezari JP, Kozal M, Aberg JA, Pialoux G, Cahn P, Thompson M, Molina JM, Moreno S, Grinsztejn B, Diaz RS, Castagna A, Kumar PN, Latiff GH, De Jesus E, Wang M, Chabria S, Gartland M, Pierce A, Ackerman P, Llamoso C. Lataillade M, et al. Lancet HIV. 2020 Nov;7(11):e740-e751. doi: 10.1016/S2352-3018(20)30240-X. Lancet HIV. 2020. PMID: 33128903 Clinical Trial.
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.
Ackerman P, Thompson M, Molina JM, Aberg J, Cassetti I, Kozal M, Castagna A, Martins M, Ramgopal M, Sprinz E, Treviño-Pérez S, Streinu-Cercel A, Latiff GH, Pialoux G, Kumar PN, Wang M, Chabria S, Pierce A, Llamoso C, Lataillade M. Ackerman P, et al. Among authors: lataillade m. AIDS. 2021 Jun 1;35(7):1061-1072. doi: 10.1097/QAD.0000000000002851. AIDS. 2021. PMID: 33946085 Free PMC article.
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals.
Anderson SJ, Murray M, Cella D, Grossberg R, Hagins D, Towner W, Wang M, Clark A, Pierce A, Llamoso C, Ackerman P, Lataillade M. Anderson SJ, et al. Among authors: lataillade m. Patient. 2022 Jan;15(1):131-143. doi: 10.1007/s40271-021-00534-y. Epub 2021 Jun 28. Patient. 2022. PMID: 34180035 Free PMC article. Clinical Trial.
Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database.
Gartland M, Arnoult E, Foley BT, Lataillade M, Ackerman P, Llamoso C, Krystal M. Gartland M, et al. Among authors: lataillade m. J Antimicrob Chemother. 2021 Oct 11;76(11):2958-2964. doi: 10.1093/jac/dkab257. J Antimicrob Chemother. 2021. PMID: 34297843 Free PMC article.
49 results